Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Frequently asked questions
What sector does Madrigal Pharmaceuticals Inc (YDO1) operate in?
Madrigal Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Madrigal Pharmaceuticals Inc (YDO1) current stock price?
As of the latest data, Madrigal Pharmaceuticals Inc stock price is €389.10, with a previous close of €388.80. Madrigal Pharmaceuticals Inc gained €0.30 in the last trading session, representing a 0.08% increase.
What is Madrigal Pharmaceuticals Inc (YDO1) current market capitalization?
Madrigal Pharmaceuticals Inc market cap is approximately 8.99 billion.
What is Madrigal Pharmaceuticals Inc (YDO1) Earnings Per Share (EPS)?
The trailing EPS is -€11.44.
What is Madrigal Pharmaceuticals Inc (YDO1) EBITDA?
Madrigal Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -43.44 million.
Does Madrigal Pharmaceuticals Inc (YDO1) pay dividends?
No. Madrigal Pharmaceuticals Inc does not pay a dividend.
When is Madrigal Pharmaceuticals Inc (YDO1) next earnings report?
Madrigal Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Madrigal Pharmaceuticals Inc (YDO1) beta (volatility) score?
Madrigal Pharmaceuticals Inc has a beta of -1.052, indicating lower volatility than the overall market.